Home Healthcare Pharmaceuticals Irritable Bowel Syndrome Treatment Market

Irritable Bowel Syndrome Treatment Market Size, Share & Trends Analysis Report By Product (Rifaximin, Eluxadoline, Lubiprostone, Linaclotide, Others), By Type (IBS with Diarrhea (IBS-D), IBS with Constipation (IBS-C), Mixed IBS), By Distribution Channel (Hospitals pharmacies, Drug Stores and Retail Pharmacies, Online pharmacies) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: June 03, 2026 | Author: Debashree B | Format: | Report Code: SR5233DR | Pages: 110
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Irritable Bowel Syndrome Treatment Market, By Product 2022-2034 (USD MILLION/ Units)
    1. Rifaximin
    2. Eluxadoline
    3. Lubiprostone
    4. Linaclotide
    5. Others
  2. Irritable Bowel Syndrome Treatment Market, By Type 2022-2034 (USD MILLION/ Units)
    1. IBS with Diarrhea (IBS-D)
    2. IBS with Constipation (IBS-C)
    3. Mixed IBS
  3. Irritable Bowel Syndrome Treatment Market, By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospitals pharmacies
    2. Drug Stores and Retail Pharmacies
    3. Online pharmacies
  4. Regional Irritable Bowel Syndrome Treatment Market
    1. North America
      1. North America Irritable Bowel Syndrome Treatment Market By Product 2022-2034 (USD MILLION/ Units)
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
      2. North America Irritable Bowel Syndrome Treatment Market By Type 2022-2034 (USD MILLION/ Units)
        1. IBS with Diarrhea (IBS-D)
        2. IBS with Constipation (IBS-C)
        3. Mixed IBS
      3. North America Irritable Bowel Syndrome Treatment Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospitals pharmacies
        2. Drug Stores and Retail Pharmacies
        3. Online pharmacies
      4. U.S.
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
        6. IBS with Diarrhea (IBS-D)
        7. IBS with Constipation (IBS-C)
        8. Mixed IBS
        9. Hospitals pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online pharmacies
      5. Canada
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
        6. IBS with Diarrhea (IBS-D)
        7. IBS with Constipation (IBS-C)
        8. Mixed IBS
        9. Hospitals pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online pharmacies
    2. Europe
      1. Europe Irritable Bowel Syndrome Treatment Market By Product 2022-2034 (USD MILLION/ Units)
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
      2. Europe Irritable Bowel Syndrome Treatment Market By Type 2022-2034 (USD MILLION/ Units)
        1. IBS with Diarrhea (IBS-D)
        2. IBS with Constipation (IBS-C)
        3. Mixed IBS
      3. Europe Irritable Bowel Syndrome Treatment Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospitals pharmacies
        2. Drug Stores and Retail Pharmacies
        3. Online pharmacies
      4. U.K.
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
        6. IBS with Diarrhea (IBS-D)
        7. IBS with Constipation (IBS-C)
        8. Mixed IBS
        9. Hospitals pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online pharmacies
      5. Germany
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
        6. IBS with Diarrhea (IBS-D)
        7. IBS with Constipation (IBS-C)
        8. Mixed IBS
        9. Hospitals pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online pharmacies
      6. France
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
        6. IBS with Diarrhea (IBS-D)
        7. IBS with Constipation (IBS-C)
        8. Mixed IBS
        9. Hospitals pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online pharmacies
      7. Spain
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
        6. IBS with Diarrhea (IBS-D)
        7. IBS with Constipation (IBS-C)
        8. Mixed IBS
        9. Hospitals pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online pharmacies
      8. Italy
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
        6. IBS with Diarrhea (IBS-D)
        7. IBS with Constipation (IBS-C)
        8. Mixed IBS
        9. Hospitals pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online pharmacies
      9. Russia
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
        6. IBS with Diarrhea (IBS-D)
        7. IBS with Constipation (IBS-C)
        8. Mixed IBS
        9. Hospitals pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online pharmacies
      10. Nordic
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
        6. IBS with Diarrhea (IBS-D)
        7. IBS with Constipation (IBS-C)
        8. Mixed IBS
        9. Hospitals pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online pharmacies
      11. Benelux
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
        6. IBS with Diarrhea (IBS-D)
        7. IBS with Constipation (IBS-C)
        8. Mixed IBS
        9. Hospitals pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online pharmacies
      12. Rest of Europe
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
        6. IBS with Diarrhea (IBS-D)
        7. IBS with Constipation (IBS-C)
        8. Mixed IBS
        9. Hospitals pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online pharmacies
    3. APAC
      1. APAC Irritable Bowel Syndrome Treatment Market By Product 2022-2034 (USD MILLION/ Units)
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
      2. APAC Irritable Bowel Syndrome Treatment Market By Type 2022-2034 (USD MILLION/ Units)
        1. IBS with Diarrhea (IBS-D)
        2. IBS with Constipation (IBS-C)
        3. Mixed IBS
      3. APAC Irritable Bowel Syndrome Treatment Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospitals pharmacies
        2. Drug Stores and Retail Pharmacies
        3. Online pharmacies
      4. China
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
        6. IBS with Diarrhea (IBS-D)
        7. IBS with Constipation (IBS-C)
        8. Mixed IBS
        9. Hospitals pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online pharmacies
      5. Korea
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
        6. IBS with Diarrhea (IBS-D)
        7. IBS with Constipation (IBS-C)
        8. Mixed IBS
        9. Hospitals pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online pharmacies
      6. Japan
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
        6. IBS with Diarrhea (IBS-D)
        7. IBS with Constipation (IBS-C)
        8. Mixed IBS
        9. Hospitals pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online pharmacies
      7. India
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
        6. IBS with Diarrhea (IBS-D)
        7. IBS with Constipation (IBS-C)
        8. Mixed IBS
        9. Hospitals pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online pharmacies
      8. Australia
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
        6. IBS with Diarrhea (IBS-D)
        7. IBS with Constipation (IBS-C)
        8. Mixed IBS
        9. Hospitals pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online pharmacies
      9. Singapore
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
        6. IBS with Diarrhea (IBS-D)
        7. IBS with Constipation (IBS-C)
        8. Mixed IBS
        9. Hospitals pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online pharmacies
      10. Taiwan
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
        6. IBS with Diarrhea (IBS-D)
        7. IBS with Constipation (IBS-C)
        8. Mixed IBS
        9. Hospitals pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online pharmacies
      11. South East Asia
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
        6. IBS with Diarrhea (IBS-D)
        7. IBS with Constipation (IBS-C)
        8. Mixed IBS
        9. Hospitals pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online pharmacies
      12. Rest of Asia-Pacific
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
        6. IBS with Diarrhea (IBS-D)
        7. IBS with Constipation (IBS-C)
        8. Mixed IBS
        9. Hospitals pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online pharmacies
    4. Middle East and Africa
      1. Middle East and Africa Irritable Bowel Syndrome Treatment Market By Product 2022-2034 (USD MILLION/ Units)
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
      2. Middle East and Africa Irritable Bowel Syndrome Treatment Market By Type 2022-2034 (USD MILLION/ Units)
        1. IBS with Diarrhea (IBS-D)
        2. IBS with Constipation (IBS-C)
        3. Mixed IBS
      3. Middle East and Africa Irritable Bowel Syndrome Treatment Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospitals pharmacies
        2. Drug Stores and Retail Pharmacies
        3. Online pharmacies
      4. UAE
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
        6. IBS with Diarrhea (IBS-D)
        7. IBS with Constipation (IBS-C)
        8. Mixed IBS
        9. Hospitals pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online pharmacies
      5. Turkey
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
        6. IBS with Diarrhea (IBS-D)
        7. IBS with Constipation (IBS-C)
        8. Mixed IBS
        9. Hospitals pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online pharmacies
      6. Saudi Arabia
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
        6. IBS with Diarrhea (IBS-D)
        7. IBS with Constipation (IBS-C)
        8. Mixed IBS
        9. Hospitals pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online pharmacies
      7. South Africa
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
        6. IBS with Diarrhea (IBS-D)
        7. IBS with Constipation (IBS-C)
        8. Mixed IBS
        9. Hospitals pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online pharmacies
      8. Egypt
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
        6. IBS with Diarrhea (IBS-D)
        7. IBS with Constipation (IBS-C)
        8. Mixed IBS
        9. Hospitals pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online pharmacies
      9. Nigeria
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
        6. IBS with Diarrhea (IBS-D)
        7. IBS with Constipation (IBS-C)
        8. Mixed IBS
        9. Hospitals pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online pharmacies
      10. Rest of MEA
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
        6. IBS with Diarrhea (IBS-D)
        7. IBS with Constipation (IBS-C)
        8. Mixed IBS
        9. Hospitals pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online pharmacies
    5. LATAM
      1. LATAM Irritable Bowel Syndrome Treatment Market By Product 2022-2034 (USD MILLION/ Units)
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
      2. LATAM Irritable Bowel Syndrome Treatment Market By Type 2022-2034 (USD MILLION/ Units)
        1. IBS with Diarrhea (IBS-D)
        2. IBS with Constipation (IBS-C)
        3. Mixed IBS
      3. LATAM Irritable Bowel Syndrome Treatment Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospitals pharmacies
        2. Drug Stores and Retail Pharmacies
        3. Online pharmacies
      4. Brazil
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
        6. IBS with Diarrhea (IBS-D)
        7. IBS with Constipation (IBS-C)
        8. Mixed IBS
        9. Hospitals pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online pharmacies
      5. Mexico
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
        6. IBS with Diarrhea (IBS-D)
        7. IBS with Constipation (IBS-C)
        8. Mixed IBS
        9. Hospitals pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online pharmacies
      6. Argentina
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
        6. IBS with Diarrhea (IBS-D)
        7. IBS with Constipation (IBS-C)
        8. Mixed IBS
        9. Hospitals pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online pharmacies
      7. Chile
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
        6. IBS with Diarrhea (IBS-D)
        7. IBS with Constipation (IBS-C)
        8. Mixed IBS
        9. Hospitals pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online pharmacies
      8. Colombia
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
        6. IBS with Diarrhea (IBS-D)
        7. IBS with Constipation (IBS-C)
        8. Mixed IBS
        9. Hospitals pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online pharmacies
      9. Rest of LATAM
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
        6. IBS with Diarrhea (IBS-D)
        7. IBS with Constipation (IBS-C)
        8. Mixed IBS
        9. Hospitals pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online pharmacies
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.